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Traceability is central to medical device software development and is an essential 
requirement for regulatory approval. To achieve compliance an effective traceability process 
needs to be in place.  This process must ensure the need for clear linkages and traceability 
from software requirements - including risks - through the different stages of the software 
development and maintenance lifecycles. This is difficult to achieve due to the lack of 
specific guidance which the medical device standards and documentation provide.  This has 
resulted in many medical device companies employing inefficient software traceability 
processes. In this paper we outline the development and implementation of Med-Trace a 
lightweight software traceability process assessment and improvement method for the 
medical device industry. We also present and discuss our findings from two industry based 
Med-Trace assessments. 
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1. Introduction  
The role and importance that software plays in medical devices continues to increase [1].  
With the demands for greater functionality in medical devices, software enables complex 
functional changes to be implemented without the requirement to change the hardware [2]. 
This has resulted in the complexity of medical device software and its development also 
increasing [3]. This has necessitated the requirement for effective traceability and risk 
management processes and tools to be in place to facilitate medical device software 
development.  
 
Due to the safety critical nature of medical device software companies  must comply with the 
regulatory requirements of the countries in which they wish to market their products [4]. This 
has resulted in governments defining regulatory requirements and establishing auditing 
bodies to ensure that only safe medical devices are placed on the market [5].  In Europe the 
requirements for medical devices are defined in the Medical Device Directive (MDD) 
(1993/42/EEC) [6]  and amendment MDD (2007/47/EC) [7], In-Vitro Diagnostic Directive 
(IVDD) (98/79/EC) [8] and the Active Implantable Medical Device Directive (AIMDD)[9] 
(90/385/EEC).  The applicable directive depends on the type of medical device being 
developed.    
 
In the US the Food and Drug Administration (FDA) are responsible for medical device 
regulation and compliance.  To provide assistance in achieving regulatory compliance the 
FDA have  published guidance documents which address risk-based activities to be 
performed during software validation [10], premarket submission [11] and when using off-
the-shelf software in a medical device [12].  Although the FDA guidance documents provide 
information on which software activities should be performed, they do not enforce any 
specific method for performing these activities. 
 
To achieve compliance national regulatory requirements also recommend conformance to a 
number of international standards which include: IEC 62304:2006 [13],  ISO 14971:2007 
[14], ISO 13485:2003 [15], EN 60601-4:2000 [16],  IEC 80002-1:2009 [17], IEC 62366:2007 
[18], IEC/TR 61508:2003 [19], and IEC 60812:2006 [20].  Given the need to address the 
requirements of these standards and regulations medical device software companies are 
compliance centric in their approach [21]. While this is essential to market their products it 
has resulted in a lack of focus on process improvement and the achievements of its associated 
benefits [5].  To address these important issues the authors are currently developing Medi 
SPICE [22, 23] a comprehensive process assessment and improvement model which is 
domain specific to medical device software development and incorporates regulatory 
compliance. In tandem with this work Med-Trace a lightweight assessment method has been 
developed which focuses on medical device software traceability.  
 
2. Medical Device Software Traceability  
In the context of software development requirements traceability refers to the ability to 
describe and follow the life of a requirement in both a forward and backward direction. This 
includes from its origins, specification, development, subsequent deployment and use and 
through periods of on-going refinement and iteration in any of these phases [24]. The focus of 
requirements traceability is identifying how high level requirements are transformed into low 
level requirements and how these are implemented and deployed in the software product. 
Traceability is also an important tool in the software development activities of project 
management, change management, risk management and defect management.  The 
deployment of an effective traceability process is essential  to facilitate the  development of  
high quality software systems [25]. It is therefore not surprising that traceability is vital for 
critical systems which must satisfy a range of functional and non-functional requirements, 
including safety, risk, reliability and availability [26].    
Medical device software development is a difficult and complex endeavour in comparison 
with other domains. Safety and risk management are two key areas which must be 
successfully addressed given the potential for harm that defective medical device software 
can cause.  Software defects are an ongoing problem for the medical device industry. This is 
highlighted by an analysis of the FDA medical device recalls from the 1st January 2010 to the 
1st January 2011. Over that period the FDA recorded 80 medical device recalls and state 
software as the cause [27] . Effective traceability is important for increasing safety and 
reducing defects in medical device software. It is also an essential requirement for regulatory 
compliance.  
In order to comply with the regulatory requirements of the medical device industry it is 
essential to have clear linkages and traceability from requirements - including risks - through 
the different stages of the software development and maintenance lifecycles.  The regulatory 
bodies require that medical device software companies clearly demonstrate how they follow a 
software development lifecycle, without providing detailed guidance on how that can be 
achieved.  This is further compounded by the requirement to adhere to numerous standards 
without guidance on how they can be implemented.  Given the lack of guidance and 
importance that traceability plays in medical device software development it was recognized 
that this was an important area which needed to be addressed. 
 
3. The Development of Med-Trace 
One of the main objectives of the Regulated Software Research Group (RSRG) in Dundalk 
Institute of Technology is to provide assistance for the improvement of medical device 
software development. Therefore, as traceability is central to the development of regulatory 
compliant software we decided to develop a lightweight assessment method specifically to 
assist companies to adhere to the traceability aspects of the medical device software standards 
and regulations.  This decision was taken in consultation with a number of multinational and 
indigenous medical devise software organizations who all highlighted the value of the 
development of such a method given the importance the traceability plays.   
Based on the Adept method [28] and Med-Adept [5], both previously developed by the 
authors, and on both the CMMI® [29] and ISO/IEC 15504-5:2006 [30] software process 
reference models, Med-Trace has been developed.  Med-Trace is a lightweight assessment 
method that provides a means of assessing the capability of an organization in relation to 
medical device software traceability. It  enables software development organizations to gain 
an understanding of the fundamental traceability best practices based on the software 
engineering traceability literature, software engineering process models (CMMI®, ISO/IEC 
15504-5), and the medical device software guidelines and standards. Med-Trace may be used 
to diagnose an organization’s strengths and weaknesses in relation to their medical device 
software development traceability practices. 
When developing Med-Trace it was very important that the requirements for traceability in 
the context of software development and in particular of medical device software 
development were defined and addressed. To achieve this, an extensive literature review was 
undertaken which focused on the following areas:  
• Generic software development and traceability 
• Safety-critical software development and traceability 
• Medical device software traceability requirements 
 
As part of the generic software development and traceability review the CMMI® [29] and 
ISO/IEC 15504-5:2006  [30] were reviewed in respect of how they addressed traceability.  In 
the area of safety-critical software traceability the DO-178B [31] standard for the aerospace 
industry and Automotive SPICE [32] for the automotive industry were among those reviewed 
and analysed. While all the relevant regulations and standards were reviewed with regard to 
medical device software.  Of these specific emphases was placed on the following as they 
proved to be the most relevant with regard to traceability: IEC 62304:2006 [13]; MDD 
(1993/42/EEC) [6]  and Amendment MDD (2007/47/EC)  [7]; FDA Center for Devices and 
Radiological Health (CDRH) Guidelines [10-12]; ISO 14071:2007 [14]; IEC/TR 80002-
1:2009 [17]; and ISO 13485:2003 [15] 
The results from the literature review identify the key aspects of the software development 
process   that Med-Trace had to focus on and address.  It also highlighted the limited amount 
of published material regarding implementation challenges and advances in the field of 
traceability in medical device software development.  This was in contrast to other sectors in 
the same context, which include automotive and aerospace software development.  It was 
therefore not a surprise to discover that while there is a requirement to address traceability, 
and undertake traceability analysis, there is limited guidance available to help implement 
traceability effectively in medical devise software organizations.  This finding is in line with 
a review of guidance for all aspects of medical device software development which took 
place in 2009 [22]. 
Based on the results from the literature review, the relevant areas of the CMMI® [29] and 
ISO/IEC 15504-5:2006 [30], and previous experience of developing lightweight process 
assessment methods  Med-Trace was developed. The goal of a Med-Trace assessment is not 
certification, but to assist medical device software organizations to gain an understanding of 
the fundamentals of traceability and best practice with the objective of improving their 
software development process.    
An important aspect of Med-Trace is the lightweight nature of the assessment.  Med-Trace is 
light in the number of personnel both internal and external to the organization that are 
required to undertake an assessment.  It is light in regard to the resources of both time and 
effort of all those involved. It is light in the time it takes to undertake and report the results of 
the assessment.   It also provides clear agreed guidelines which can be achieved in a short 
time period which will facilitate process improvement with tangible results with regard to 
traceability.       
 
3.1 Stages of the Med-Trace Assessment Method 
The Med-Trace assessment method contains eight specific stages which are sequentially 
undertaken. The assessment team normally consists of two assessors who share responsibility 
for conducting the assessment. Stage 1, a preliminary meeting between the assessment team 
and the company wishing to undergo a Med-Trace assessment takes place.  At this meeting 
the assessment team discuss the main drivers for the company embarking on a Med-Tace 
assessment and an assessment schedule is agreed. During stage 2, the lead assessor provides 
an overview of the Med-Trace assessment to members of the organization who will be 
involved in subsequent stages of the assessment. At stage 3, a review is undertaken which 
provides a brief insight into project documentation.  The first three stages are normally 
performed on the company’s premises, but the sample documentation collected in stage 3 is, 
normally taken off-site as it can then be used to assist with the generation of additional 
questions for stage 4. The assessment team return onsite to commence stage 4 when key staff 
members from the organization are interviewed. A set of scripted questions are used for these 
interviews which are based on the software traceability literature review, the CMMI® [29] 
and ISO/IEC 15504-5 [30] models, and traceability practices that are required by the medical 
device industry. Each Interview is normally scheduled to take 1.5 hours approximately and 
the number of interviews that take place is limited to a maximum of 4.  
Stage 5 is a collaborative exercise which the assessors jointly undertake to develop the 
findings report using their respective interview notes. Stage 6 involves presenting the 
findings report to participating staff in the organization. The focus of stage 7 is the 
collaborative development with the staff of a pathway towards achieving highly effective and 
regulatory compliant traceability practices. The findings report will provide guidance to the 
assessed company and will focus on practices that will offer the greatest benefit in terms of 
the company’s business goals and objectives, in addition to quality and compliance. Stage 8 
involves revisiting and reassessing the company approximately 3 months after the completion 
of stage 7 and reviewing progress against the recommended improvement path. The outcome 
of this stage is an updated improvement path and a final report detailing the progress that has 
been accomplished along with additional recommendations.  
 
4. The Implementation of Two Med-Trace Assessments 
In this section we outline our observations from undertaking two Med-Trace assessments, 
one in an Irish company and the other in a company based in the United Kingdom. The 
process improvement objectives that were collaboratively agreed by both organizations to 
improve their respective traceability practices are presented.  We also discuss our 
observations from our findings from undertaking both assessments. 
 
4.1 Med-Trace Assessment in Medical Electronic 
The first assessment took place in a small to medium sized (SME) Irish medical device 
organization, Medical Electronic (a pseudonym). Medical Electronic develop electronic 
based medical devices that are marketed in the US and Europe.  To sell their products they 
require compliance with both the FDA and the MDD.    The importance traceability plays in 
medical device software development was recognized by Medical Electronic and they sought 
a lightweight assessment method to obtain guidance as to how they could improve their 
traceability process.  Having been introduced to Med-Trace and having discussed what was 
involved they requested a Med-Trace assessment.  
 
4.1.1 Medical Electronic Med-Trace Assessment Recommendations  
Based on the analysis of the results from the Med-Trace assessment undertaken in Medical 
Electronic and in collaboration with their staff, an improvement plan was developed with the 
following recommendations: 
1. The organization will undertake steps to measure the time spent on traceability and 
evaluate its effectiveness.    
2. In future projects the task of performing traceability will be identified as part of the 
project plan and adequate time and resources will be allocated to undertake this task.   
3. Good practices which are employed while performing the traceability process will be 
documented in an efficient format and will be available for dissemination to relevant parties 
as and when required.  
4. Project managers will mandate the use of traceability while conducting impact 
analysis, promoting its usage as a management tool and enabling the capture of information 
for management use. 
5. Milestones will be put in place in the software development lifecycle which will not 
permit advancement to other phases/stages of the lifecycle until the requirements for 
traceability are satisfied.  
6. A mechanism for tracing open bugs/known issues to the safety/hazard/risk 
management sys-tem and linking them to the requirements will be put in place and utilised.  
7. The organization will evaluate and select a tool for the process of automating 
traceability and requirements management.  
 
4.2 Med-Trace Assessment in North Medical UK 
The second Med-Trace assessment took place in a United Kingdom based medical device 
organization, North Medical UK (a pseudonym).  North Medical UK is an SME and they 
develop electronic-based medical devices that require compliance with both the FDA and the 
MDD. North Medical UK also sought a resource-light assessment method to obtain guidance 
as to how they could improve their software development traceability process.  Having heard 
about the Med-Trace assessment method they contacted the authors and after discussions 
regarding what was involved they requested an assessment.  
 
4.2.1 North Medical UK Med-Trace Assessment Recommendations  
Having analysed the results from the Med-Trace assessment and in collaboration with North 
Medical UK staff, an agreed pathway for improvement was developed: 
1. The software development traceability process will be formalised and documented. 
2. Meetings between the various parties involved in traceability will be scheduled as part 
of the development life cycle 
3. A formal training program will be introduced to facilitate the adoption of best 
traceability practices for requirements and risk management.  
4. The current MS Office based traceability application will be replaced with an 
appropriate automated traceability tool.  
5. Terminology usage with regard to traceability will be standardised and a formal 
definition of both risk and hazard agreed. A formal method for quantifying probability of 
harm will also be introduced and deployed. 
6. A traceability and validation procedure will be developed, implemented and 
monitored to verify the activities of the staff that perform the traceability and validation 
function. 
7. A formal procedure will be developed and implemented to facilitate mapping from the 
design documentation to the software code.     
8. Resources will be allocated to enable the full implementation of an automated tool.  
This tool has been purchased to allow digital signatures to be recorded at each development 
stage, but it has not been properly implemented. 
4.3 Observations - Implementing Two Med-Trace Assessments 
The organizations assessed both recognized the importance traceability plays in medical 
device software development. This was reflected in the fact that in both organizations a 
member of the management team was responsible for its implementation.  The difficult and 
complexity involved in successfully tracing requirements and managing risk and hazards 
were appreciated by both organizations. The lack of detailed guidance on how to implement 
traceability was highlighted by the management of Medical Electronic and North Medical 
UK. While these organizations both employed a process for traceability they recognized this 
needed to be improved and formalized.  The requirement for relevant training and the ability 
to record and leverage best practice with regard to traceability also emerged.   
The serious limitations of utilising manual tools such as MS Office to manage traceability 
was clearly recognized as a problem.  As was the requirement for the procurement of 
automated tools to address this very important issue. It was understood that this had to be 
undertaken with due care and within the financial and temporal constraints of both 
organizations. 
 
Both organizations welcomed the opportunity to participate in a Med-Trace assessment.   The 
fact that it is lightweight and specifically addressed key issues was considered very relevant 
and valuable.  The findings from the assessments identified important areas where 
improvements were required and this was confirmed in consultation with the management 
and staff of both organizations.   The adoption of the development pathway provided realistic 
goals and the collaborative process provided motivation for their achievement.  Both 
organizations are implementing their respective development pathways and have agreed to be 
reassessed as part of stage 8 of the Med-Trace assessment method. 
 
5. Conclusions and Future Plans 
Due to the critical nature of medical device software and the potential harm failure can cause, 
the implementation of an effective traceability process is essential. Therefore, to ensure 
validity, software requirements traceability analysis needs to be conducted to trace software 
requirements to (and from) system requirements, and to risk analysis results. While this is 
mandated by the medical device guidelines and standards it is recognized as difficult to 
accomplish.  The lack of detailed guidance and direction as to how this can be successfully 
achieved has been highlighted as a particular problem in this context. While the need to 
provide requirements traceability cannot be underestimated, the necessity to provide 
traceability for each identified hazard is of equal importance.  Risk management is a key 
activity for medical device software development and hazards have to be traced to risk 
analysis, risk evaluation and the implementation and verification of the risk control measures.   
Med-Trace helps to address these issues by providing a lightweight traceability centric 
assessment method that organizations can utilise.  The focus is on a resource light assessment 
that can pinpoint specific areas for improvement with regard to traceability that will provide 
tangible results in a short time period.  The need for the collaborative development of the 
improvement path is essential to en-sure relevance and buy in within the assessed 
organization.  The opportunity for reassessment provides an updated improvement plan and 
the final report contains additional recommendations and highlights what improvements have 
been achieved.   The RSRG at Dundalk Institute of Technology will continue to refine Med-
Trace based on the experience gained in undertaking future assessments, interaction with 
medical device software organisations and medical device regulatory bodies. It is envisaged 
that further research will be under taken for the development of similar lightweight 
assessment methods.  These will deal with other important aspects of medical device software 
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